$LWLG Lightwave Logic, Inc. CEO Sends Open Letter to

New Post Public Reply Private Reply Replies (0) Message Board
mc67
605
$LWLG Lightwave Logic, Inc. CEO Sends Open Letter to Shareholders

ENGLEWOOD, CO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Lightwave Logic, Inc. (OTCQB: LWLG) announced today that it sent an Open Letter to its Shareholders.

Open Letter to Lightwave Logic, Inc. Shareholders

Fellow Shareholders,

I would like to take the opportunity to bring all of you up to-date with the incredible progress we have been making this year. With so much going on, I have decided to begin to provide quarterly shareholder letters. You can expect to receive the next letter in January 2019.

In this quarter we have received terrific feedback from prospective customers, the team is energized and motivated by our continued progress. In all ways, we are encouraged by the validation of our belief that we are positioning ourselves ahead of our competitors.

Let me bring your attention to this last statement: positioning ahead of our competitors. Recall that 2 years ago we were aiming for a 3 Gbps polymer modulator. We have successfully caught up with the competition since then. In my personal experience in this highly technical and complex field, this is an almost unheard-of short period of time. Since then we have progressed very quickly from 10Gbps operating modulators in early 2017, to 25Gbps operating modulators in mid-2017, to 50Gbps operating modulators by late 2017, to packaged 50Gbps modulators in May 2018. Per the presentation at the ASM, we are continuing our development of the 50Gbaud (capable of 50 Gbps and above, see [1]) packaged modulator prototypes, and we are looking in parallel to accelerate work on 100Gbaud polymer modulators which are well ahead of any existing products on the market.

By being ahead, we appear to be gaining significant market leverage through technical advantage. Market leverage in this sense does not relate to financial leverage but to a specific competitive strength. For example, a technology or product may be perceived by customers as being unique rather than competing head-to-head with standard products.

Our position must be protected, and we do that with a combination of a strengthening patent portfolio and increased number of protected trade secrets and know-how. For example, one of our recently published patent applications [2] teaches the use of low voltage, very high-speed polymer modulators that embodies our market leverage. Other modulator technologies are struggling not only to achieve 100Gbaud but also to get their voltage level down to 1V.

We have received feedback that our P2IC™ platform with tiny 100Gbaud polymer modulators with low voltage electrical bias are extremely attractive for the next generation fiber optic transceivers. At the recent ECOC conference (European Conference on Optical Communications) we heard potential customers express concerns about technological limits of conventional technologies. This prestigious commercial trade show is where leading companies market their products and plan purchases of optoelectronics equipment. Our talk there spoke directly to addressing those concerns. In the highly visible Market Focus session [1] we showed that our polymer modulators have industry-matching performance at 50Gbaud, but also the capability of breaking these technological limits at 100Gbaud. A Tier 1 customer prospect for our modulators said, “you guys are in the forefront right now”.

Our Lightwave team at continues to have extremely high esprit des corps and is working diligently to meet our goals. We design, fabricate and characterize our modulators at our new HQ facility in Englewood, Colorado. We are still working closely with our packaging partner for the 50Gbaud prototypes, and we are advancing our reliability and characterization efforts to support our prototyping. We are actively engaged with test equipment manufacturers to deliver the most advanced test equipment for our state-of-the-art polymer results. Based on our experience in this industry, we expect the customer design-in process to start with initial evaluation of our samples and reliability data, proceeding to more extensive evaluation, optimization, and possible customization.

We continue to fine tune our business model with target markets, customers, and technical specifications. Discussions with prospective customers are validating that our modulators are ideally suited for the datacenter and telecommunications markets that are over 10km in length. Details of what they want from a prototype are fed back to the technical team. The team is more energized and focused than ever.

We are happy to report that we are making excellent progress and are on track to achieve the goals we set out at our ASM in May 2018.

Looking forward

We know that our shareholders believe this is a very slow a process, but in my experience at being both an industrial entrepreneur and intrapreneur (an intrapreneur is an entrepreneur inside a big corporation), our progress over the past couple of years is no less than incredible. We have a world-class team, and we are focused on our goals. I am personally proud of everyone on our team and our board. We appear to be poised to become a market leader with 100Gbaud, 1V tiny polymer modulators.

Thank you for your continuing support.

Michael Lebby

CEO

References:

[1] ECOC Presentation 2018, Rome, Italy

http://lightwavelogic.com/external.asp?b=2252...;ID=175125

[2] Patent Application: DIRECT-DRIVE POLYMER MODULATOR METHODS OF FABRICATING AND MATERIALS THEREFOR

Publication number: 20180259798

Powered by Lightwave Logic

Lightwave Logic, Inc. is a development stage company moving toward commercialization of next generation photonic devices using its high-activity and high-stability organic polymers for applications in data communications and telecommunications markets. Photonic electro-optical devices convert data from electric signals into optical signals. For more information about the Company please visit the corporate website at: www.lightwavelogic.com.

______________________________________________

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, lack of available funding; general economic and business conditions; competition from third parties; intellectual property rights of third parties; regulatory constraints; changes in technology and methods of marketing; delays in completing various engineering and manufacturing programs; changes in customer order patterns; changes in product mix; success in technological advances and delivering technological innovations; shortages in components; production delays due to performance quality issues with outsourced components; those events and factors described by us in Item 1.A “Risk Factors” in our most recent Form 10-K; other risks to which our Company is subject; other factors beyond the Company's control.

Karen Liu
Lightwave Logic, Inc.
+1 720 262 8143
karen@lightwavelogic.com

Lightwave Logic Inc (LWLG) Stock Research Links

LWLG Board Company Profile Buy Rating Time & Sales News Filings Financials
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 313

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 193

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 128

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 224

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 332

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 134

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 541

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Phreesia Announces Q3 Fiscal Year 2025 Financial Results

Updated Category News Views 71

Phreesia to Release Fiscal Q3 2025 Results Soon Phreesia, Inc. (NYSE: PHR) has great news for its stakeholders! The company revealed plans to announce its financial results for the third quarter of fiscal year 2025 right after market closing on a Monday in December. During this quarter, the firm experienced substantial growth and is eager to share the details with the...

Continue Reading
Innovative Water Bowl Design Enhances Pet Hydration Experience

Updated Category News Views 374

Revolutionary Pet Water Bowl Crafted for Optimal Hydration Every pet owner knows the importance of keeping their furry friends hydrated, especially during hot days. A new invention promises to enhance the experience for pets and their owners alike. This innovative water bowl, known as the THERMA DRINK, is designed with features that cater directly to pet needs. The idea...

Continue Reading
HPH's Leadership Changes Signify Strategic Direction Ahead

Updated Category News Views 177

Leadership Transitions at HPH Highest Performances Holdings Inc. (NASDAQ: HPH) has recently seen a notable change in its Board of Directors. The company announced that Mr. Peh Chin Hua's tenure as Director has come to an end, effective immediately. This decision is part of a broader strategy aimed at strengthening the Board's overall composition and capabilities. Current...

Continue Reading
Apranga Group Reports Growth in Retail Turnover for 2025

Updated Category News Views 132

Apranga Group Retail Performance Overview for 2025 Apranga Group, a major player in the retail sector, has announced its impressive financial performance for the first six months of 2025, demonstrating notable growth compared to the prior year. The company's retail turnover reached a commendable EUR 166.1 million, reflecting a 2.8% increase from the same period in 2024....

Continue Reading
IMUNON Unveils Promising New Vaccine Data for COVID-19

Updated Category News Views 154

New Vaccine Insights from IMUNON's Phase 1 Clinical Trial The innovative PlaCCine technology platform developed by IMUNON, Inc. (NASDAQ: IMNN) promises remarkable durability and advantages over traditional mRNA vaccines, particularly in the struggle against COVID-19. Robust Results from IMNN-101 Vaccine Trials In an encouraging announcement, IMUNON shared pivotal data...

Continue Reading